http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111848626-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2020-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111848626-B |
| titleOfInvention | TRK kinase inhibitors and their uses |
| abstract | The present invention discloses a TRK kinase inhibitor and use thereof. The TRK kinase inhibitor of the present invention is shown in formula (I), and also provides a preparation method of the compound and a pharmaceutical composition comprising these kinase inhibitors and its use in the prevention and treatment of cancer; the novel compound shown in formula I disclosed in the present invention exhibits good TRK inhibitory activity, and provides a new choice for clinical treatment of diseases related to abnormal TRK activity, |
| priorityDate | 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.